| PSMB10 — Proteasome Subunit Beta Type-10 | |
|---|---|
| Symbol | PSMB10 |
| Full Name | Proteasome Subunit Beta Type-10 |
| Also Known As | LMP10, MECL-1, beta2i |
| Chromosome | 16p11.2 |
| NCBI Gene | 10226 |
| Ensembl | ENSG00000100578 |
| OMIM | 607589 |
| UniProt | P40306 |
| Protein Class | Protease, Hydrolase |
| Diseases | Alzheimer's Disease, Parkinson's Disease, Proteasome Dysfunction |
| Expression | Brain, Immune System, Lung |
Psmb10 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PSMB10 (Proteasome Subunit Beta Type-10), also known as LMP10 (Low Molecular Weight Proteome 10) or MECL-1 (Multicatalytic Endopeptidase Complex-Like 1), is a gene encoding a catalytic subunit of the immunoproteasome. Located on chromosome 16p11.2, PSMB10 plays a critical role in the proteolytic activity of the immunoproteasome, contributing to MHC class I antigen processing and cellular protein homeostasis [1][2].
The immunoproteasome is a specialized variant of the standard 20S proteasome that is induced by inflammatory cytokines, particularly interferon-gamma (IFN-γ). PSMB10 represents one of three inducible catalytic subunits (alongside PSMB8/LMP7 and PSMB9/LMP2) that replace their constitutive counterparts in the immunoproteasome complex, altering its substrate specificity and proteolytic activity [3].
Research has increasingly implicated PSMB10 in neurodegenerative diseases, where dysregulated proteasome function contributes to protein aggregate accumulation, neuroinflammation, and neuronal death characteristic of conditions such as Alzheimer's disease and Parkinson's disease [4][5].
PSMB10 encodes the beta2i subunit of the immunoproteasome. This subunit replaces the constitutive beta2 subunit (PSMB7) in the immunoproteasome complex, conferring trypsin-like proteolytic activity. The immunoproteasome assembly process involves:
The resulting immunoproteasome exhibits altered cleavage preferences, generating peptides with C-terminal residues optimized for MHC class I binding [1][3].
PSMB10 mediates the trypsin-like proteolytic activity of the immunoproteasome:
The trypsin-like activity of PSMB10 complements the chymotrypsin-like (PSMB8) and caspase-like (PSMB9) activities of other immunoproteasome subunits, ensuring comprehensive substrate processing [3].
Beyond antigen processing, PSMB10 participates in cellular protein quality control:
In Alzheimer's disease (AD), PSMB10 expression is significantly altered:
The immunoproteasome upregulation in AD may represent:
In Parkinson's disease (PD), PSMB10 dysregulation affects:
Studies have demonstrated increased PSMB10 expression in PD brain, particularly in dopaminergic neurons and surrounding microglia [6]. This may reflect:
PSMB10 plays a dual role in neuroinflammation:
The balance of these effects may determine whether PSMB10 contributes to neurodegeneration or neuroprotection [5][6].
PSMB10 demonstrates distinct expression patterns:
In the central nervous system:
PSMB10 represents a potential therapeutic target for:
Autoimmune diseases: Immunoproteasome inhibitors are being developed for conditions such as multiple sclerosis and rheumatoid arthritis [7].
Neurodegenerative diseases: Modulating PSMB10 activity may help:
Cancer immunotherapy: Immunoproteasome targeting can modulate antigen presentation in tumor cells [7].
The study of Psmb10 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.